Abstract
Metabolomics has emerged as a mainstream approach for investigating complex metabolic phenotypes but has yet to be integrated into routine clinical diagnostics. Metabolomics-based diagnosis of urinary tract infections (UTIs) is a logical application of this technology since microbial waste products are concentrated in the bladder and thus could be suitable markers of infection. We conducted an untargeted metabolomics screen of clinical specimens from patients with suspected UTIs and identified two metabolites, agmatine and N6-methyladenine, that are predictive of culture positive samples. We developed a 3.2-minute LC-MS assay to quantify these metabolites and showed that agmatine and N6-methyladenine correctly identify UTIs caused by 13 Enterobacterales species and 3 non-Enterobacterales species, accounting for over 90% of infections (agmatine AUC > 0.95; N6-methyladenine AUC > 0.89). These markers were robust predictors across two blinded cohorts totaling 1,629 patient samples. These findings demonstrate the potential utility of metabolomics in clinical diagnostics for rapidly detecting UTIs.
Competing Interest Statement
Drs. Lewis, Gregson and Mr. Groves are authors on a patent relating to the use of LC-MS for detecting urinary tract infections. No other competing interests declared.
Funding Statement
This work was supported by Genome Canada (10019200), the Canadian Institute of Health Research (162790), the University of Calgary (Biomedical Engineering 10011121), and Alberta Precision Laboratories. I.A.L is supported by an Alberta Innovates Translational Health Chair. T.R. is supported by an Eyes-High Postdoctoral Fellowship from the University of Calgary. S.D.W. was supported in part by an NSERC Undergraduate Summer Research Award. Metabolomics data were acquired at the Calgary Metabolomics Research Facility, which is supported by the International Microbiome Centre and the Canada Foundation for Innovation (CFI-JELF 34986).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Calgary's Conjoint Health Research Ethics Board, under certificate # REB16-0167
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Added an additional blinded cohort of 1,042 clinical specimens to the results and discussion; Performed creatinine normalization; Added Figure 4; Revised Supplementary Datasets and Figures; Revised the introduction and discussion regarding the performance of N6-methyladenine and we have now emphasized it as a suitable biomarker for 3 specific non-Enterobacterales infections (A. urinae, S. aureus, S. saprophyticus); Performed additional statistical analyses on all datasets and included confidence intervals of all reported AUCs; Methods section has been updated to provide clarity of our dilute and shoot LC-MS assay for blinded cohort 2; Expanded our discussion to address the potential use of a combinatorial biomarker assay, and further discuss the uses and limitations of the agmatine and N6-methyladenine screening assays, with respect to patient demographics, clinical applications, and point-of-care tools.
Data availability
All data are available in the main text or the supplementary materials. Raw mass spectrometry data are available from the study team upon request.
